Table 1.
Baseline characteristics of patients in the study groups.
| Characteristic | Group | |
|---|---|---|
| OMB-OIT treated (N = 10) | Untreated (N = 6) | |
| Gender (male) | 5 (50%) | 6 (100%) |
| Age at the challenge test | ||
| Median (Range) | 9.5 (8.3–10) | 9.5 (7.5–10.8) |
| Initial total IgE level (IU/mL) | ||
| Median (IQR) | 1993 (1198–4117.5) | 1852.5 (635.2–2895.8) |
| Initial CM-specific IgE level (kUA/L) | ||
| Median (IQR) | 85 (43.5–151) | 60.9(30.8-92.1) |
| Initial Casein, β-lact, α-lact, -specific IgE level | ||
| Casein, Median (IQR, kUA/L) | 97.0 (48.5–140.5) | 52.3 (39.5-183) |
| β-lact, Median (IQR, kUA/L) | 16.2 (7.5–38.5) | 12.8 (2.8–43.7) |
| α-lact, Median (IQR, kUA/L) | 3.7 (1.7–8.6) | 2.0 (1-25.8) |
| Wheal diameter of SPT (mm) | ||
| Fresh CM Median (IQR) | 11.3 (10.3–14.8) | 15 (9.5–21.3) |
| MH-CM Median (IQR) | 12.5 (7–16.5) | 9.3 (8.6–18.9) |
| Standard CM exact Median (IQR) | 11 (9.6–14.8) | 16 (9.5–22.1) |
| Histamine Median (IQR) | 7.3 (6–7.9) | 7 (4.5-8.1) |
| Presence of Other Food Allergies | ||
| No | 10 (%) | 0 |
| Yes | 90 (%) | 6 (100%) |
| Frequency of anaphylaxis at accidental ingestion | ||
| Never | 1 (10%) | 1 (17%) |
| Once | 5 (50%) | 1 (17%) |
| 2-10 times | 3 (30%) | 4 (66%) |
| >10 times | 1 (10%) | 0 |
| Atopic dermatitis | 6 (60%) | 3 (50%) |
| Asthma | ||
| Severity of asthma* | 3 (30%) | 4 (66%) |
| Intermittent | 3 (30%) | 3 (50%) |
| Moderate | 0 | 1 (16%) |
| Persistent | 0 | 0 |
| SCD of CMP at DBPCFC (mg), median (IQR) | 43 (10.8–43) | 0 (0–32.5) |
| SCD of CM at fresh OFC (mL), median (IQR) | 1.8 (0.8–1.8) | 0.6 (0.3–0.8) |
| SCD of CM at MH-OFC (mL), median (IQR) | 1.8 (0.8–3.3) | 1.8 (0.8–3.3) |
OMB: omalizumab, OIT: oral immunotherapy, β-lact: β-lactoglobulin, α-lact: α-lactoalbumin, MH: microwave heated, CM: cow’s milk, OFC: open food challenge, #Grade of anaphylaxis according to Sampson’s grading score24, DBPCFC: double-blind placebo controlled food challenge, IQR: interquartile range, CMP: cow’s milk protein, SCD: successfully comsumed dose, *Severity of asthma according to Japanese Pediatric Guideline for the treatment and management of bronchial asthma37.